Damora Therapeutics is a clinical-stage biopharmaceutical company developing targeted antibody therapies for myeloproliferative neoplasms (MPNs), a group of chronic bone marrow cancers. Damora focuses specifically on patients whose MPNs are driven by mutations in a protein called calreticulin (mutCALR), which drives roughly 25% of essential thrombocythemia (ET) cases and 35% of myelofibrosis (MF) cases. Damora's lead candidate, DMR-001, is a monoclonal antibody designed to selectively bind mutCALR on cancer cells while leaving normal cells unaffected — a contrast to current treatments like JAK inhibitors and hydroxyurea, which broadly suppress blood cell production. Preclinical data showed DMR-001 has approximately ten-fold greater potency against Type 2 mutCALR and a five-fold longer half-life versus a reference antibody with the same mechanism as Incyte's INCA033989. These properties are designed to enable infrequent subcutaneous self-injection, vs. Incyte's IV infusion every two weeks — a meaningful distinction for patients requiring lifelong treatment. Damora also holds options on two additional mutCALR-targeting candidates, DMR-002 and DMR-003, a bispecific T cell engager. Damora has no approved products or revenue and operates on the standard clinical-stage biotech model: raise equity capital and invest in R&D toward regulatory approval, with a potential path to either independent commercialization or out-licensing. The company outsources manufacturing to CMOs. Damora's current form emerged from a November 2025 reverse merger in which Galecto Biotech acquired private Damora Therapeutics and raised $285M in a PIPE, followed by a ~$297M follow-on offering.